Table 1.
Market share of interventions considered in the scenarios with and without RefluxStop
| Treatment | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Scenario without RefluxStop (all scenarios) | |||||
| Nissen fundoplication | 89.7% | 89.6% | 89.5% | 89.4% | 89.3% |
| MSA | 10.3% | 10.4% | 10.5% | 10.6% | 10.7% |
| Base case scenario with RefluxStop | |||||
| RefluxStop | 5.1% | 10.2% | 15.2% | 18.5% | 21.8% |
| Nissen fundoplication | 84.6% | 79.4% | 74.3% | 70.9% | 67.6% |
| MSA | 10.3% | 10.4% | 10.5% | 10.6% | 10.7% |
| Scenario with RefluxStop (reduced rate of RefluxStop uptake) | |||||
| RefluxStop | 2.6% | 5.1% | 7.6% | 9.3% | 10.9% |
| Nissen fundoplication | 87.2% | 84.5% | 81.9% | 80.2% | 78.4% |
| MSA | 10.3% | 10.4% | 10.5% | 10.6% | 10.7% |
| Scenario with RefluxStop (increased rate of RefluxStop uptake) | |||||
| RefluxStop | 10.3% | 20.4% | 30.4% | 37.0% | 43.6% |
| Nissen fundoplication | 79.5% | 69.3% | 59.1% | 52.4% | 45.8% |
| MSA | 10.3% | 10.4% | 10.5% | 10.6% | 10.7% |
MSA magnetic sphincter augmentation